Navigation Links
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Date:6/12/2013

THOUSAND OAKS, Calif. and GAITHERSBURG, Md., June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced that they will present data from a Phase 2 study evaluating brodalumab, a human monoclonal antibody targeting the IL-17 receptor, being investigated for the treatment of psoriatic arthritis at the 2013 European League Against Rheumatism (EULAR) Annual Meeting in Madrid, June 12-15, 2013. 

"The brodalumab data being presented at EULAR demonstrate a positive benefit-risk profile for patients with psoriatic arthritis," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We are encouraged by these data as we continue to explore brodalumab for its potential to treat patients with inflammatory disease including psoriatic arthritis."

Based on the Phase 2 results, the companies intend to advance brodalumab into Phase 3 clinical studies for the treatment of psoriatic arthritis in 2014.

"This brodalumab data marks a positive step forward for patients with psoriatic arthritis," said Dr. Bahija Jallal, executive vice president, MedImmune.  "We look forward to working with Amgen to further evaluate this novel therapy in psoriatic arthritis and potentially other chronic immune-mediated diseases."

ABSTRACT OF INTEREST:

Brodalumab Abstract at EULAR:

  • Efficacy of Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis
    Abstract No. OP0103, Oral Presentation, Thursday, June 13, 10:20 a.m. CET, N117

Abstracts are currently available on the EULAR website at www.eular.org.

About Brodal
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the Federal ... the public comment period (Docket No. FAA-2014-0396) for FAA’s ... by Congress as part of the FAA Modernization and ... new deadline for comments as September 23, 2014. , ... in the Federal Register on July 25, 2014, the ...
(Date:7/24/2014)... Tenn., July 24, 2014 -- A novel combination of ... Department of Energy,s Oak Ridge National Laboratory an unprecedented ... its unusual physical and electrochemical properties. , The ... oxygen affects the surface of a perovskite manganite, a ... The new avenue to understand surface behavior could benefit ...
(Date:7/24/2014)... July 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ... field of regenerative medicine, announced today that it ... to investors on Tuesday, July 29, 2014, at ... will include an overview of Asterias, business strategy ... visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes ...
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2ORNL study reveals new characteristics of complex oxide surfaces 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... , THOROLD, ON , ... innovative privately held Canadian biotechnology company focusing primarily on ... purification, today announced the launch of 10 new kits ... from blood, plasma and serum, including circulating nucleic acids. ...
... , Collaboration will further evaluate novel stem cell-derived ... genes relevant to disease progression , CAMBRIDGE, Mass. ... California Stem Cell, Inc. (CSC) and ALS Therapy Development ... expansion of their collaboration aimed at advancing a potential stem ...
... SANTA ROSA, Calif. , Feb. 2 Just in ... introduces the newest in their scientifically formulated product line: CIRCUTOL™ Cardiovascular ... in 1995 by integrative medicine pioneer, Dr. Isaac Eliaz ... being at the forefront of the latest developments in natural alternative health ...
Cached Biology Technology:Norgen Biotek Launches 10 New Kits for the Isolation of High-Quality Circulating Nucleic Acids from Blood, Plasma and Serum 2California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 2California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 3California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 4Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 2Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 3
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... identified two factors that characterize sustainable university and ... highly qualified physics teachers. Specifically, one or more ... education in combination with institutional motivation and commitment ... Technology, Engineering and Math (STEM) teacher shortages are ... the way for institutions seeking to increase the ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2
... 25, 2010 - A first-of-its-kind study of a Caspian ... current harvest rates are four to five times higher ... results, which will be published in an upcoming issue ... conservation strategies for beluga sturgeon should focus on reducing ...
... A study involving the world,s deadliest substance has yielded a ... to more efficient strategies against toxins that may be used ... stings, and even some important chronic diseases. A ... agents that seek out Botulinum toxin molecules and bind to ...
... as they evolved over hundreds of generations to infect bacteria. ... the viruses evolved at a quicker rate and generated greater ... adapt to the viral infection. The study shows, for ... Valen was correct in his ,Red Queen Hypothesis,. The ...
Cached Biology News:New research shows fishery management practices for beluga sturgeon must change 2New research shows fishery management practices for beluga sturgeon must change 3Novel antitoxin strategy developed using 'tagged binding agents' 2Novel antitoxin strategy developed using 'tagged binding agents' 3Scientists reveal driving force behind evolution 2
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... Optics LIBS2000+ Spectrometers (sold separately) in the ... Chamber to offer numerous configuration options and ... include a high-power 1064 nm Nd:YAG laser, ... sample positioning, laser spot diameter control from ...
... Picking,A modified digital scanner serves as the ... the five standard rack positions on the ... micro well plates on the remaining two ... single spots by mouse-click on the scanned ...
Biology Products: